MannKind Corporation Reports 2021 First Quarter Financial Results

Westlake Village, California, UNITED STATES

Conference Call to Begin Today at 5:00 PM ET

  • 1Q 2021 Total Revenues of $17.4 million; +7% vs. 1Q 2020
  • Received $230.0 million gross proceeds from 2.5% senior convertible notes
  • $278.3 million of Cash, Cash Equivalents and Investments at March 31, 2021
  • Tyvaso DPI™ NDA submitted to the FDA by collaboration partner United Therapeutics

WESTLAKE VILLAGE, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the quarter ended March 31, 2021.

“We started 2021 by taking advantage of favorable market conditions to strengthen our financial position with the issuance of $230 million of senior convertible notes, which provides our current and future partners with greater confidence in our company,” said Michael Castagna, Chief Executive Officer of MannKind Corporation. “The capital raised allows us to reduce our legacy debt, advance our pipeline and grow Afrezza. In the first quarter of 2021, the underlying demand for paid Afrezza prescriptions grew in the mid-single digits year over year.”

Total revenues were $17.4 million for the first quarter of 2021, an increase of $1.2 million, or 7%, reflecting Afrezza net revenue of $8.1 million and collaboration and services revenue of $9.3 million. Afrezza net revenue increased 1% compared to $8.0 million in the first quarter of 2020. Collaboration and services revenue for the first quarter of 2021 increased $1.1 million compared to the first quarter of 2020, primarily due to additional pass-through costs associated with the UT license agreement and the launch of the Vista Pharma Co-promotion Agreement for Thyquidity. 

Afrezza gross profit for each of the first quarters of 2021 and 2020 was $3.8 million. Cost of goods sold increased by $0.2 million compared to the same period in 2020, which was offset by the increase in net revenues discussed above. Gross margin in the first quarter of 2021 was 47% compared to 48% for the same period in 2020.

Research and development expenses for the first quarter of 2021 were $2.4 million compared to $1.8 million for the first quarter of 2020. This increase of $0.7 million, or 39%, was attributable to personnel costs primarily related to increased headcount for research and development, regulatory and medical affairs.

Selling, general and administrative expenses for the first quarter of 2021 were $17.4 million compared to $14.4 million for the first quarter of 2020. This increase of $3.1 million, or 21%, was primarily due to a $2.3 million increase in personnel costs primarily related to increased headcount for our Afrezza commercial team, $0.3 million in patient support services and $0.3 million in promotional and marketing activities.  

For the first quarter of 2021, the gain on foreign currency translation for insulin purchase commitments denominated in Euros was $3.8 million compared $1.8 million for the first quarter of 2020. The fluctuation was due to the change in the U.S. dollar to Euro foreign exchange rate. Interest expense on debt for the first quarter of 2021 was $6.5 million compared to $2.3 million for the first quarter of 2020. This increase of $4.1 million was due to a $3.7 million milestone obligation that was achieved during the quarter and interest expense from the senior convertible notes and the MidCap credit facility.  

The net loss for the first quarter of 2021 was $12.9 million, or $0.05 per share, compared to a $9.3 million net loss in the first quarter of 2020, or $0.04 per share. The increased net loss of $3.6 million was primarily due to the increase in interest expense, selling, general and administrative expenses, and research and development expense, all of which were partially offset by an increase in the gain on foreign currency translation.

Cash, cash equivalents, and investments at March 31, 2021 were $278.3 million compared to $67.0 million at December 31, 2020. The increase in cash, cash equivalents and investments was primarily due to the issuance of $230.0 million of 2.5% senior convertible notes.

Debt Reductions Subsequent to March 31, 2021

In April 2021, the Company repaid $35.1 million outstanding principal under the Mann Group non-convertible promissory note plus $4.9 million of accrued and unpaid interest to the Mann Group. In addition, the Company repaid $10.0 million outstanding principal under the MidCap credit facility.

Conference Call

MannKind will host a conference call and presentation webcast to discuss these results today at 5:00 p.m. Eastern Time. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at under Events & Presentations.  A replay will be available on MannKind's website for 14 days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.  Afrezza is also available by prescription in Brazil where it is commercialized by the Company’s partner Biomm SA.  MannKind is headquartered in Westlake Village, California, and has a manufacturing and R&D facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding MannKind’s ability to directly commercialize pharmaceutical products. Words such as “believes”, “anticipates”, “plans”, “expects”, “intend”, “will”, “goal”, “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the MannKind’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the ability to generate significant product sales for MannKind, MannKind’s ability to manage its existing cash resources or raise additional cash resources, stock price volatility and other risks detailed in MannKind’s filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2020 and subsequent periodic reports on Form 10-Q and current reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

Tyvaso DPI is an investigational combination product that is not approved for any use in any country. The Tyvaso DPI tradename is pending final FDA review.

Company Contact:

(In thousands, except share and per share data)

  March 31, 2021  December 31, 2020 
Current assets:        
Cash and cash equivalents $247,833  $67,005 
Restricted cash  158   158 
Short-term investments  28,962    
Accounts receivable, net  3,573   4,218 
Inventory  5,050   4,973 
Prepaid expenses and other current assets  2,766   3,122 
Total current assets  288,342   79,476 
Property and equipment, net  26,507   25,867 
Long-term investments  1,480    
Other assets  3,053   3,265 
Total assets $319,382  $108,608 
Current liabilities:        
Accounts payable $6,706  $5,582 
Accrued expenses and other current liabilities  27,586   19,707 
PPP loan — current  4,670   4,061 
Deferred revenue — current  25,880   33,275 
Recognized loss on purchase commitments — current  8,274   11,080 
Total current liabilities  73,116   73,705 
Senior convertible notes  222,855    
MidCap credit facility  49,406   49,335 
Mann Group promissory notes  53,453   63,027 
Accrued interest — Mann Group promissory notes  4,753   4,150 
PPP loan — long term  203   812 
2024 convertible notes     5,000 
Recognized loss on purchase commitments — long term  80,797   84,208 
Operating lease liability  869   1,202 
Deferred revenue — long term  1,626   1,662 
Milestone rights liability  5,926   5,926 
Total liabilities  493,004   289,027 
Stockholders' deficit:        
Undesignated preferred stock, $0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding as of March 31, 2021 and December 31, 2020      
Common stock, $0.01 par value - 400,000,000 shares authorized, 249,072,677 and 242,117,089 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively  2,491   2,421 
Additional paid-in capital  2,885,946   2,866,303 
Accumulated deficit  (3,062,059)  (3,049,143)
Total stockholders' deficit  (173,622)  (180,419)
Total liabilities and stockholders' deficit $319,382  $108,608 

(In thousands, except per share data)

 Three Months Ended
March 31,
 2021  2020 
Net revenue — commercial product sales$8,099  $8,000 
Revenue — collaborations and services 9,337   8,235 
Total revenues 17,436   16,235 
Cost of goods sold 4,315   4,164 
Cost of revenue — collaborations and services 3,295   3,362 
Research and development 2,442   1,755 
Selling, general and administrative 17,413   14,350 
Asset impairment    1,521 
Gain on foreign currency translation (3,838)  (1,796)
Total expenses 23,627   23,356 
Loss from operations (6,191)  (7,121)
Other (expense) income:       
Interest income 3   133 
Interest expense on notes (5,422)  (1,071)
Interest expense on Mann Group promissory notes (1,030)  (1,259)
Other expense (276)  (4)
Total other expense (6,725)  (2,201)
Loss before provision for income taxes (12,916)  (9,322)
Provision for income taxes     
Net loss$(12,916) $(9,322)
Net loss per share - basic and diluted$(0.05) $(0.04)
Shares used to compute basic and diluted net loss per share 246,631   212,467